Condition

Neoplasms, Prostatic

ClinicalTrials.gov condition label

Clinical trials4

Recruiting0

Common interventions7

Lead sponsors shown4

Clinical trials

4 shown

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate CancerNCT02649855 · 2016-01-19

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate CancerNCT02349139 · 2015-01-19

Sipuleucel-T Manufacturing Demonstration StudyNCT01477749 · 2012-06-01

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate CancerNCT00970203 · 2009-09-01

Common interventions

androgen ablation (AA)BIOLOGICAL1 ASN001: Escalating dose Part ADRUG1 DC1 vaccineBIOLOGICAL1 DocetaxelDRUG1 PROSTVAC-FBIOLOGICAL1 PROSTVAC-VBIOLOGICAL1 sipuleucel-TBIOLOGICAL1

Leading sponsors

Asana BioSciences1 Dendreon1 National Cancer Institute (NCI)1 Roswell Park Cancer Institute1

Trial status mix

COMPLETED3

TERMINATED1

Phase mix

PHASE23

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.